1. Intravenous tranexamic acid reduce postoperative drainage and pain after open elbow arthrolysis: a randomized controlled trial
- Author
-
Cunyi Fan, Ziyang Sun, Jihao Ruan, Juehong Li, Shiyang Yu, Shuai Chen, and Haomin Cui
- Subjects
Visual analogue scale ,medicine.medical_treatment ,Elbow ,Blood Loss, Surgical ,Pain ,Postoperative Hemorrhage ,Placebo ,Elbow pain ,Hematoma ,medicine ,Humans ,Orthopedics and Sports Medicine ,Ulnar nerve ,Saline ,business.industry ,General Medicine ,medicine.disease ,Antifibrinolytic Agents ,medicine.anatomical_structure ,Tranexamic Acid ,Anesthesia ,Drainage ,Administration, Intravenous ,Surgery ,business ,Tranexamic acid ,medicine.drug - Abstract
Background Open elbow arthrolysis (OEA), which has become an established treatment for post-traumatic elbow stiffness (PTES), requires complete release of contracture tissue and wide excision of ectopic bone, which results in extensive bleeding. The aim of the present study is to evaluate the efficacy of intravenous tranexamic acid (TXA) on postoperative drainage, calculated blood loss, and early clinical outcomes in patients undergoing OEA. Methods A double-blind, randomized, placebo-controlled trial including 96 patients undergoing OEA was undertaken. Patients received intravenously either 100 mL saline (placebo group, n = 48), or 100 mL saline plus 1 g TXA (TXA group, n = 48) before skin incision. The primary outcome was the drainage volume on postoperative days (PODs) 1-3. Secondary outcomes included the calculated blood loss, elbow pain score measured by visual analog scale (VAS), elbow function valued by Mayo Elbow Performance Score (MEPS), and rate of complications after OEA. Results Mean total postoperative drainage volume (TXA group: 182 mL vs. placebo group: 214 mL, P = .003) and mean calculated total blood loss (TXA group: 582 mL vs. placebo group: 657 mL, P = .004) were significantly lower in the TXA group. No transfusions were necessary in either group. Mean VAS pain scores in elbow motion showed marked differences between both groups on POD 1 (TXA: 5 vs. placebo: 6, P = .003) and POD 2 (TXA: 4 vs. placebo: 5, P = .023) but not in other postoperative time points. No differences were detected in complications, such as pin-related infection, hematoma, new or exacerbation of ulnar nerve symptoms, and recurrent heterotopic ossification. At the 6-month follow-up, no statistical differences were found between the 2 groups with respect to the elbow functions including range of motion, VAS score, and MEPS. Conclusion Intravenous administration of TXA significantly decreased the postoperative drainage volume and the total estimated blood loss and alleviated the elbow pain with motion during early postoperative days in patients undergoing OEA.
- Published
- 2021
- Full Text
- View/download PDF